How Putnam’s CEO Matt Riordan Is Accelerating Cancer Therapy Adoption | ASCO 2025 Highlights

At ASCO 2025, Matt Riordan, CEO of Putnam Associates, part of Inizio Advisory, shares expert insights on the future of cancer treatment, commercialization strategy, and accelerating the adoption of next-gen therapies across clinical settings. 🔑 Highlights ✅ Key challenge: ensuring adoption across both academic and community oncology ✅ Faster clinician and patient education = faster uptake of breakthrough drugs ✅ Real-world strategy behind the launch of the first CAR-T therapy ✅ AI in oncology: overhyped or underutilized? Why human judgment still matters ✅ Aligning medical, commercial, and access teams around a unified strategy ✅ Inizio’s integrated approach: turning strategy into action across the lifecycle ✅ Why the real win is accelerating access for patients—without delay This episode is sponsored by Inizio. #ASCO2025 #PutnamAssociates #InizioAdvisory #OncologyStrategy #CancerInnovation #CAR_T #RadioligandTherapy SUBSCRIBE to get the latest #oncodaily    / @oncodailytv   Visit the OncoDaily Website : https://oncodaily.com Like OncoDaily on LinkedIn:   / oncodaily   Like OncoDaily on X (Twitter): https://x.com/oncodaily Follow OncoDaily on Instagram:   / oncodailynews   Follow OncoDaily on TikTok:   / oncodaily   Like OncoDaily on Facebook:   / oncodaily   SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter About OncoDaily OncoDaily is your trusted source for the latest oncology news, expert interviews, patient stories, and cutting-edge research. Our mission is to empower the global cancer community—patients, survivors, professionals, and advocates—with timely, credible information. Subscribe for weekly podcasts, expert conversations, and updates on groundbreaking cancer research. 🔔 New videos every day! 💻 Visit us at https://oncodaily.com/